Five Prime Therapeutics Total Revenue

The latest total revenue for FPRX is $13M as of December 2020. That compares with $15M in the prior-year period — down 11.4% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Five Prime Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FPRX's total revenue moved from $15M to $13M — a 11.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Five Prime Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, FPRX currently prints $13M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Five Prime Therapeutics's growth, margins, and balance sheet.

A total revenue figure of $13M for FPRX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting FPRX's total revenue ($13M), review year-over-year change from $15M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.